Diagnostic Yield of 2 Strategies for Adult Celiac Disease Identification in Primary Care.


Journal

Journal of clinical gastroenterology
ISSN: 1539-2031
Titre abrégé: J Clin Gastroenterol
Pays: United States
ID NLM: 7910017

Informations de publication

Date de publication:
01 2019
Historique:
pubmed: 20 12 2017
medline: 21 3 2020
entrez: 20 12 2017
Statut: ppublish

Résumé

To compare the diagnostic yield and cost-consequences of 2 strategies, screening regardless of symptoms versus case finding (CF), using a point-of-care test (POCT), for the detection of celiac disease (CD) in primary care, to bridge the diagnostic gap of CD in adults. All subjects under 75 years of age who consecutively went to their general practitioners' offices were offered POCT for anti-transglutaminase immunoglobulin A antibodies. The POCT was performed on all subjects who agreed, and then a systematic search for symptoms or conditions associated with higher risk for CD was performed, immediately after the test but before knowing the test results. The 2 resulting groups were: (a) POCT positive and (b) symptomatic subject at CF. Subjects were defined as symptomatic at CF in the presence of 1 or more symptoms. All POCT-positive or symptomatic subjects at CF were referred to the CD Centers for confirmation of CD. Data on resource consumption were gathered from patients' charts. Cost of examinations, and diagnostic and laboratory tests were estimated with regional outpatient tariffs (Sicily), and a price of &OV0556;2.5 was used for each POCT. Of a total of 2197 subjects who agreed to participate in the study, 36 (1.6%) and 671 (30.5%) were POCT positive and symptomatic at CF, respectively. The yield from the screening and CF was 5 new celiac patients. The total cost and mean cost for each new CD case were &OV0556;7497.35 and &OV0556;1499.47 for the POCT screening strategy, and &OV0556;9855.14 and &OV0556;1971.03 for the CF strategy, respectively. Assuming consecutive use of both strategies, performing POCT only in symptomatic subjects at CF, the calculated yield would be 4 new diagnoses with a total cost of &OV0556;2345.84 and a mean cost of &OV0556;586.46 for each newly diagnosed patient. Only 1 patient was celiac despite a negative POCT. Testing symptomatic subjects at CF only by POCT seems the most cost-effective strategy to bridge the diagnostic gap of adult CD in primary care.

Identifiants

pubmed: 29256989
doi: 10.1097/MCG.0000000000000962
doi:

Substances chimiques

Immunoglobulin A 0
Transglutaminases EC 2.3.2.13

Types de publication

Comparative Study Journal Article Multicenter Study Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

15-22

Auteurs

Riccardo Scoglio (R)

Sicilian Celiac Disease Study Group.

Gianluca Trifirò (G)

Department of Biomedical and Dental Sciences and Morphofunctional Imaging.

Antonino Sandullo (A)

Sicilian Celiac Disease Study Group, Sciacca (Agrigento).

Giovanni Marangio (G)

Sicilian Celiac Disease Study Group.

Cinzia D'Agate (C)

Celiac Disease Regional Center, Gastroenterology and Endoscopy Unit, University of Catania.

Stefano Costa (S)

Celiac Disease Regional Center.

Salvatore Pellegrino (S)

Celiac Disease Regional Center.

Angela Alibrandi (A)

Medical Statistics, Department of Economics, University of Messina.

Andrea Aiello (A)

Creativ-Ceutical, Milan.

Giovanni Currò (G)

Celiac Disease Regional Center.

Chiara Cuzzupè (C)

Celiac Disease Regional Center.

Fabrizio Comisi (F)

Celiac Disease Regional Center, Vittoria (Ragusa).

Salvatore Amato (S)

Celiac Disease Regional Center, Vittoria (Ragusa).
Sicilian Celiac Disease Study Group, Catania.

Roberto Conti Nibali (R)

Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy.

Sergio Oteri (S)

Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy.

Giuseppe Magazzu (G)

Celiac Disease Regional Center.

Antonio Carroccio (A)

Celiac Disease Regional Center, Internal Medicine, Giovanni Paolo II Hospital, Sciacca (Agrigento).
DiBiMIS University of Palermo, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH